Xcout Intel
Trogenix competitors & alternatives
The 12 closest competitors and alternatives to Trogenix among healthcare companies — ranked by similarity to what Trogenix actually does, not by market-cap band.
Subscribe to see Trogenix’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Trogenix
Trogenix is a privately held biotechnology research company that stands at the forefront of cancer therapy innovation, combining genomics, synthetic biology, and oncology disease models. The company runs clinical trials, such as the Phase I/II trial for its TGX-007 gene therapy to treat glioblastoma.
Trogenix at a glance
Trogenix is a healthcare company headquartered in United Kingdom. Its most recent funding round, Series A, raised $95M in October 2025. Xcout tracks 6 named people at Trogenix, including Dr. Ken Macnamara (Chief Executive Officer).
Trogenix leadership
- Dr. Ken MacnamaraChief Executive Officer
- Dr. Juan Manuel IglesiasChief Technology Officer
- Atif Abbas, MDChief Medical Officer
- Dr. Dima KuzminChairman
- Prof. Steve PollardChief Scientific Officer and Founder
- Tay SalimullahChief Strategy Officer and Board Member
Trogenix funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $95M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Trogenix competitors
Ranked by semantic similarity — how close each company is to Trogenix by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar healthcare company
Imagenomix is a biotechnology research company headquartered in New York City that develops artificial intelligence models to enhance cancer clinical trials and precision medicine.
Similar healthcare company
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
Similar healthcare company
GEMMABio is a privately held therapeutics company founded in 2024 in Philadelphia, Pennsylvania, dedicated to developing novel gene therapies for rare diseases.
Biotech
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Biotech
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Biotech
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Biotechnology
Core Biomedicine is a preclinical-stage biotechnology and pharmaceutical manufacturing company pioneering lineage-based precision oncology therapeutics.
Biotech
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Biotech
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Biotech
Genetix Biotherapeutics develops and delivers one-time, curative genetic therapies for patients suffering from rare, severe genetic diseases such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The company utilizes patients' own blood stem cells, modifying them outside the body to correct underlying genetic defects and restore normal function. It serves patients, families, and healthcare providers by providing these advanced treatments alongside dedicated clinical support and research programs.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Trogenix and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Trogenixand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →